Abstract
BackgroundPatients (pts) with rheumatoid arthritis (RA) and a history of atherosclerotic cardiovascular (CV) disease (HxASCVD) have a higher risk of major adverse CV events (MACE) with tofacitinib vs tumour necrosis...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
